Literature DB >> 20615627

Risk factors for cataract after palladium-103 ophthalmic plaque radiation therapy.

Paul T Finger1, Kimberly J Chin, Guo-Pei Yu, Neil S Patel.   

Abstract

PURPOSE: To examine how tumor characteristics and dose affect cataract development after plaque radiation therapy. METHODS AND MATERIALS: Three hundred and eighty-four patients were diagnosed with uveal melanoma and treated with palladium-103 ((103)Pd) plaque radiation therapy. Of these, 282 (74%) inclusion met exclusion criteria for follow-up time, tumor location, and phakic status. Then patient-, ophthalmic-, and radiation-specific factors (patient age, diabetes, hypertension, tumor location, tumor dimensions, and lens dose) were examined (by a Cox proportional regression model) as predictors for the development of radiation-related cataract.
RESULTS: Radiation cataract developed in 76 (24%) of patients at a mean follow-up of 39.8 months (range, 1-192). Patients with anteriorly located tumors were noted to have a higher incidence of cataract at 43.0% (43 of 100 patients) vs. 18.1% (33 cataracts per 182 patients) for posteriorly located tumors (p <0.0001). However, multivariate Cox proportional modeling showed that increasing patient age at time of treatment (p for trend = 0.0003) and higher lens dose (p for trend = 0.001) were the best predictors (biomarkers) for radiation cataract.
CONCLUSIONS: Although anterior tumor location, greater tumor height, and increased patient age (at treatment) were associated with significantly greater risk for radiation cataract, dose to lens was the most significant factor.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20615627     DOI: 10.1016/j.ijrobp.2010.02.051

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  4 in total

1.  Comparison of dose calculation methods for brachytherapy of intraocular tumors.

Authors:  Mark J Rivard; Sou-Tung Chiu-Tsao; Paul T Finger; Ali S Meigooni; Christopher S Melhus; Firas Mourtada; Mary E Napolitano; D W O Rogers; Rowan M Thomson; Ravinder Nath
Journal:  Med Phys       Date:  2011-01       Impact factor: 4.071

Review 2.  Current and emerging treatment options for uveal melanoma.

Authors:  Patricia Rusa Pereira; Alexandre Nakao Odashiro; Li-Anne Lim; Cristina Miyamoto; Paula L Blanco; Macanori Odashiro; Shawn Maloney; Dominique F De Souza; Miguel N Burnier
Journal:  Clin Ophthalmol       Date:  2013-08-22

3.  103Pd versus 125I ophthalmic plaque brachytherapy: preoperative comparative radiation dosimetry for 319 uveal melanomas.

Authors:  Paul T Finger; Di Zhou; Nina Kalach; Ekaterina Semenova; Walter Choi
Journal:  J Radiat Oncol       Date:  2014-04-09

4.  Palladium-103 plaque brachytherapy for retinoblastoma: Long term follow up.

Authors:  Abhilasha Maheshwari; Paul T Finger
Journal:  Am J Ophthalmol Case Rep       Date:  2022-06-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.